NRx Pharmaceuticals, Inc.
NRXPNASDAQHealthcare● Active
$4.33
+$0.19(+4.59%)
Market Cap$74847142
P/E Ratio—
52W High$5.055
52W Low$1.62
NRx Pharmaceuticals, Inc. (NRXP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NRXP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.04
Est. -$0.05 · +20.0%
Revenue
$0.00B
Est. $0.02B · -94.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
NRXP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.09 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.05 | -$0.04 | +20.0% | $0.00B | $0.02B | -94.5% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.09 | $0.19 | +311.1% | $0.00B | $0.01B | -86.9% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.11 | -$0.18 | -63.6% | $0.00B | $0.01B | -96.8% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.30 | -$0.34 | -13.3% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 14, 2025 | -$0.20 | -$0.30 | -50.0% | $0.00B | $0.01B | -99.9% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.81 | -$0.15 | +81.5% | — | — | — |
| ▲ Q3 FY2024 | Aug 14, 2024 | -$0.81 | -$0.75 | +7.4% | — | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.05
EPS Surpr.
+20.0%
Revenue
$0.00B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
$0.19
EPS Est.
-$0.09
EPS Surpr.
+311.1%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.11
EPS Surpr.
-63.6%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.30
EPS Surpr.
-13.3%
Revenue
$0.00B
Q1 FY2025
Mar 14, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.20
EPS Surpr.
-50.0%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.15
EPS Est.
-$0.81
EPS Surpr.
+81.5%
Revenue
—
Q3 FY2024
Aug 14, 2024Beat
EPS Actual
-$0.75
EPS Est.
-$0.81
EPS Surpr.
+7.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $2.20 | $4.40 | $6.60 | 1 |
| Q2 FY2029 | $2.21 | $4.41 | $6.61 | 1 |
| Q1 FY2029 | $2.12 | $4.24 | $6.36 | 1 |
| Q4 FY2028 | $2.85 | $5.69 | $8.53 | 1 |
| Q3 FY2028 | $2.74 | $5.47 | $8.21 | 1 |
| Q2 FY2028 | $2.74 | $5.48 | $8.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.3B | $0.6B | $0.8B | 1 |
| Q2 FY2029 | $0.3B | $0.6B | $0.8B | 1 |
| Q1 FY2029 | $0.3B | $0.5B | $0.7B | 1 |
| Q4 FY2028 | $0.2B | $0.3B | $0.4B | 1 |
| Q3 FY2028 | $0.2B | $0.3B | $0.4B | 1 |
| Q2 FY2028 | $0.2B | $0.3B | $0.4B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +20.0% | $3.21 | $3.28 | +2.18% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +311.1% | $1.85 | $1.77 | -4.32% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -63.6% | $2.59 | $2.49 | -3.86% |
| ▼ Q2 FY2025 | May 15, 2025 | -13.3% | $2.27 | $2.40 | +5.73% |
| ▼ Q1 FY2025 | Mar 14, 2025 | -50.0% | $2.07 | $2.35 | +13.53% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +81.5% | $1.25 | $1.16 | -7.20% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +7.4% | $1.90 | $1.86 | -2.11% |
| ▼ Q2 FY2024 | May 14, 2024 | -34.5% | $2.99 | $3.18 | +6.35% |
Q2 FY2026+2.18%
Report Date
May 15, 2026
EPS Beat/Miss
+20.0%
Price Before
$3.21
Price After
$3.28
Q1 FY2026-4.32%
Report Date
Mar 23, 2026
EPS Beat/Miss
+311.1%
Price Before
$1.85
Price After
$1.77
Q4 FY2025-3.86%
Report Date
Nov 14, 2025
EPS Beat/Miss
-63.6%
Price Before
$2.59
Price After
$2.49
Q2 FY2025+5.73%
Report Date
May 15, 2025
EPS Beat/Miss
-13.3%
Price Before
$2.27
Price After
$2.40
Q1 FY2025+13.53%
Report Date
Mar 14, 2025
EPS Beat/Miss
-50.0%
Price Before
$2.07
Price After
$2.35
Q4 FY2024-7.20%
Report Date
Nov 14, 2024
EPS Beat/Miss
+81.5%
Price Before
$1.25
Price After
$1.16
Q3 FY2024-2.11%
Report Date
Aug 14, 2024
EPS Beat/Miss
+7.4%
Price Before
$1.90
Price After
$1.86
Q2 FY2024+6.35%
Report Date
May 14, 2024
EPS Beat/Miss
-34.5%
Price Before
$2.99
Price After
$3.18
Avg Beat Reaction-2.86%
Avg Miss Reaction+5.44%
Beat Rate4 / 8 quarters
Largest Move+13.53% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NRXP ends December
NRx Pharmaceuticals, Inc. (NRXP) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.04 — beating the analyst consensus of $-0.05 by +20.0%. NRXP has beaten EPS estimates for 2 consecutive quarters. The next NRXP earnings date is expected around September 1, 2026.
Each quarter, investors track NRXP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NRXP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NRXP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NRXP earnings · 5 questionsNRx Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. NRXP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NRXP historically reports after market close (AMC).
NRXP earnings datewhen is NRXP earningsNRXP next earnings datewhen does NRXP report earningsNRXP earnings calendar
▸ Source: FMP · NRx Pharmaceuticals, Inc. SEC filings · US GAAP · NRx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026